PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced that it has appointed Brian Koh, M.D., as its Chief Medical Officer. In this new role, Dr. Koh will be responsible for developing and executing the company’s clinical development and medical strategy, serving on PrognomiQ’s Executive Team.
Read the full article here.
January 8, 2024
PrognomiQ’s Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer
Read More
January 23, 2023
PrognomiQ’s Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer
Read More